RG
GBT

Redmile Group’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Redmile Group’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-188,000
Closed -$9.89M – 87
2019
Q2 		$9.89M Buy
188,000
+20,400
+12% +$1.17M 0.28% 57
2019
Q1 		$8.87M Hold
167,600
– – 0.26% 58
2018
Q4 		$6.88M Buy
+167,600
New +$6.28M 0.28% 56
2017
Q3 		– Sell
-631,283
Closed -$17.3M – 75
2017
Q2 		$17.3M Sell
631,283
-303,060
-32% -$9.02M 1.05% 35
2017
Q1 		$34.4M Buy
934,343
+617,943
+195% +$15.6M 2.23% 16
2016
Q4 		$4.57M Buy
+316,400
New +$5.56M 0.39% 40
2016
Q1 		– Sell
-218,718
Closed -$7.07M – 59
2015
Q4 		$7.07M Sell
218,718
-44,174
-17% -$1.91M 0.53% 37
2015
Q3 		$11.1M Buy
+262,892
New +$12.4M 0.84% 28

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Redmile Group's GBT Position: Q3 2019 in Review

Redmile Group sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2019, closing a stake of 188,000 shares — an estimated $9.89M sold.

Redmile Group first reported a position in GBT in Q3 2015 and held it in 8 quarters. The position peaked at $34.4M in Q1 2017. 208 funds tracked by Wall St. Rank hold GBT as of Q3 2019.

  • Redmile Group reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Redmile Group sold 188,000 Global Blood Therapeutics, Inc. shares in Q3 2019, an estimated $9.89M.
  • Redmile Group first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 8 quarters.
  • Redmile Group's Global Blood Therapeutics, Inc. position peaked at $34.4M in Q1 2017.
  • 208 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2019.

Based on Redmile Group's 13F filing for Q3 2019, filed 14 Nov 2019.